US Compounding Revenue and Competitors
Estimated Revenue & Valuation
- US Compounding's estimated annual revenue is currently $14.9M per year.
- US Compounding's estimated revenue per employee is $201,000
Employee Data
- US Compounding has 74 Employees.
- US Compounding grew their employee count by -13% last year.
US Compounding's People
| Name | Title | Email/Phone |
|---|
US Compounding Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7M | 35 | 6% | N/A | N/A |
#2 | $14.9M | 74 | -13% | N/A | N/A |
#3 | $95.1M | 473 | N/A | N/A | N/A |
#4 | $0.3M | 3 | 0% | $50M | N/A |
#5 | $18.7M | 93 | 3% | N/A | N/A |
#6 | $1.6M | 8 | -27% | N/A | N/A |
#7 | $5.4M | 27 | 8% | N/A | N/A |
#8 | $10.7M | 53 | 10% | N/A | N/A |
What Is US Compounding?
PCAB accredited compounding-only pharmacy specializing in sterile injectables, bioidentical hormone replacement, the autism spectrum, topical pain therapy, veterinary compounds, and much more. Licensed in over 40 states, US Compounding serves patients, physicians, and surgery centers across the country with the highest-quality compounded medications, helping them solve unique problems in the lives and practices.
keywords:Healthcare,Pharmaceuticals
N/A
Total Funding
74
Number of Employees
$14.9M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
US Compounding News
And the U.S. dollar's leading role in global finance and borrowing means the Federal Reserve's rapid conversion to the need for tighter...
* The U.S. Food and Drug Administration has issued final guidance on compounding animal drugs from bulk drug substances, a policy nearly 20...
US Injectable Compounding Pharmacy Market Size Worth USD 2,153.2 Million by 2028, with Improved Longevity Due to Customized Medicines.
Other Companies in Conway
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.9M | 75 | 0% | N/A |
#2 | $7.5M | 83 | 4% | N/A |
#3 | $23.8M | 88 | 2% | N/A |
#4 | $30.4M | 92 | -5% | N/A |
#5 | $22.2M | 98 | 36% | N/A |